EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Molecular Mechanisms and Therapeutic Strategies to Overcome Resistance to Endocrine Therapy and CDK4/6 Inhibitors in Advanced ER+/HER2− Breast Cancer

Paola Ferrari iD, Maria Luisa Schiavone, Cristian Scatena iD, Andrea Nicolini iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26073438 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Paola Ferrari und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Pisa University Hospital, Via Roma 57, 56126 Pisa, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms, Drug Resistance, Neoplasm, Cyclin-Dependent Kinase 6, Cyclin-Dependent Kinase 4. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Approximately 70–80% of breast cancers are estrogen receptor-positive (ER+), with 65% of these cases also being progesterone receptor-positive (ER+PR+). In most cases of ER+ advanced breast cancer, endocrine therapy (ET) serves as the first-line treatment, utilizing various drugs that inhibit ER signaling. These include tamoxifen, a selective estrogen receptor modulator (SERM); fulvestrant, a selective estrogen receptor degrader (SERD); and aromatase inhibitors (AIs), which block estrogen synthesis. However, intrinsic or acquired hormone resistance eventually develops, leading to disease progression. The combination of ET with cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) has been shown to significantly increase progression-free survival (PFS) and, in some cases, overall survival (OS). CDK4/6is works by arresting the cell cycle in the G1 phase, preventing DNA synthesis, and enhancing the efficacy of ET. This review highlights the key mechanisms of resistance to ET, whether used alone or in combination with biological agents, as well as emerging therapeutic strategies aimed at overcoming resistance. Addressing ET resistance remains a work in progress, and in the near future, better patient selection for different therapeutic approaches is expected through the identification of more precise biological and genetic markers. In particular, liquid biopsy may provide a real-time portrait of the disease, offering insights into mechanisms driving ET resistance and cancer progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsDrug Resistance, NeoplasmCyclin-Dependent Kinase 6Cyclin-Dependent Kinase 4Protein Kinase InhibitorsAntineoplastic Agents, HormonalHumansFemaleReceptors, EstrogenErb-b2 Receptor Tyrosine KinasesAnimals

Stichwörter der Autor:innen

CDK4/6 inhibitorsadvanced ER+/HER2− breast cancerendocrine resistanceendocrine therapy

Substanzen

Cyclin-Dependent Kinase 6Cyclin-Dependent Kinase 4Receptors, EstrogenErb-b2 Receptor Tyrosine KinasesProtein Kinase InhibitorsAntineoplastic Agents, HormonalCDK6 protein, humanCDK4 protein, humanERBB2 protein, human

Autor:innen und Institutionen

  • Department of Oncology, Pisa University Hospital, Via Roma 57, 56126 Pisa, Italy.
  • Division of Pathology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy.

ORCID-Profile: Paola Ferrari, Cristian Scatena, Andrea Nicolini

Zitieren

APA

Ferrari, P., Schiavone, M. L., Scatena, C., & Nicolini, A. (2025). Molecular Mechanisms and Therapeutic Strategies to Overcome Resistance to Endocrine Therapy and CDK4/6 Inhibitors in Advanced ER+/HER2− Breast Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26073438

Vancouver

Ferrari P, Schiavone ML, Scatena C, Nicolini A. Molecular Mechanisms and Therapeutic Strategies to Overcome Resistance to Endocrine Therapy and CDK4/6 Inhibitors in Advanced ER+/HER2− Breast Cancer. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26073438

BibTeX
@article{Ferrari2025,
  author = {Ferrari, Paola and Schiavone, Maria Luisa and Scatena, Cristian and Nicolini, Andrea},
  title = {Molecular Mechanisms and Therapeutic Strategies to Overcome Resistance to Endocrine Therapy and CDK4/6 Inhibitors in Advanced ER+/HER2− Breast Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26073438}
}
Kostenlos starten →